FDA approves Lilly's oral GLP-1 Foundayo (orforglipron) for weight loss
The small-molecule pill can be taken at any time of day without food or water restrictions, unlike existing oral peptide options.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 1 03:00 ETSource: Eli Lilly
The wire
- 01The FDA approved Foundayo (orforglipron), Lilly's oral GLP-1 for weight loss, which the company says requires no food or water timing restrictions.
- 02An oral incretin without dosing-window rules changes counseling and adherence planning for prescribers and pharmacists who have managed oral semaglutide's fasting requirements.
- 03Launch pricing, payer coverage and real-world tolerability will determine uptake; Lilly began shipping to pharmacies in April.
From the source
Read at investor.lilly.comFDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions